Introduction
The inflammatory bowel diseases (IBDs) of Crohn's disease (CD) and ulcerative colitis (UC) are chronic relapsing inflammatory disorders of the gut, which often impair quality of life. [1] [2] [3] [4] The main symptoms of these conditions are urgent and frequent diarrhea, pain, and profound fatigue and anemia, often associated with inflammation of joints, skin or eyes. Malnutrition and weight loss are also common. The disease is not curable and follows an unpredictable relapsing and remitting course with a significant variation in the pattern and complexity of symptoms that affect each patient. IBD affects approximately one person in every 250 in the UK population. 5 Quality of life (QoL) measures provide an important insight into patients' perception of their health and how the treatments they receive affect it. To measure QoL in clinical practice, it is important to develop instruments that are short and effective and yet valid, reliable and applicable to all IBD patients, whether managed in the community or acutely admitted to hospital. A valid, reliable and short measure would also be of use in research and for IBD registries, particularly to monitor outcomes after treatment with new therapies. 6 There has been some success in using generic instruments, such as the Short Form (SF)36, 7 the Psychological General Wellbeing Scale, 8, 9 the generic 15D instrument, 10, 11 and the Questions on Life Satisfaction (FLZ) in the IBD questionnaire (IBDQ). 12 However, there are concerns that these instruments might miss small but clinically important changes. 13 There are several condition-specific QoL measures for patients with IBD, [14] [15] [16] [17] [18] [19] of which the McMaster IBDQ [14] [15] [16] 20 is the most widely used. Another common quality of life measure in the UK is the UK-IBDQ, 21 which was developed in 2000 and validated for use in outpatient clinics. However, these measures have not become a routine part of daily clinical practice and are often overlooked in large-scale registries because of the limitations on the amount of data these registries can collect and the large number of patients with IBD managed in outpatient clinics. A tool that is simple to use, quickly performed and short will increase the regular use of QoL measures in longitudinal patient care.
The aim of this study was to develop a short QoL questionnaire suitable for use with patients with IBD, whether they have stable or mildly active disease managed in outpatient clinics, or more severe disease that may require acute admission to hospital.
Materials and methods

Devising the items
Items were generated through a literature search and an expert panel review of two gastroenterologists, three outcome measurement experts and a statistician. The panel included authors of the UK-IBDQ, a 30 item questionnaire that was validated in 2000 on patients with stable IBD managed in the community 21 . The panel reviewed and modified the UK-IBDQ to develop questions needed to assess the QoL of patients with acute IBD admitted to hospital and also stable patients managed in outpatient clinics. A focus group of patients with IBD was included in the initial development of the QoL questionnaire. The new QoL measure is called the Crohn's and ulcerative colitis questionnaire (CUCQ).
To test for acceptability and lack of ambiguity, we carried out a pilot study on 20 patients with IBD. The purpose of this pilot study was to check the clarity of the items and the time required by patients to complete the questionnaires. In addition to the CUCQ, we asked consenting patients to provide verbal or written feedback or annotations regarding the content and format of the questionnaire. At the end of the questionnaire, we asked them four supplementary questions and invited them to explain their responses: 
The recruitment process and sample size
We used CUCQ to collect data from a convenience sample of outpatients and inpatients with IBD in four large hospitals in South Wales, UK, between January 2012 and September 2013.
There is no rule in the literature about the number of patients required to validate the QoL measures. However, a ratio of 5 or 10 patients per item was suggested 22 . Recent studies have suggested that 100 patients or more are sufficient for a proper validation study. 23 We aimed for a sample size of at least 160 patients for the purpose of validating the CUCQ questionnaire. We also checked the Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy (which should be >0.5) and Bartlett's test of sphericity (which should be significant) to confirm that the sample was suitable for principal component analysis, which we will discuss later. [24] [25] [26] The inclusion criteria were: confirmed diagnosis of UC or CD; at least 18 years of age; a native English speaker; and absence of severe mental illness. Patients who met the inclusion criteria were approached when they attended outpatient clinics, during other treatment-related visits (e.g. having biological therapy), when having endoscopic examination, or when admitted to hospital. We explained the study to patients orally and in writing and obtained their consent. The patients completed the CUCQ questionnaire as well as two generic QoL measures which were the EuroQol 5 Dimensions (EQ5D) 27 and the Short Form 12 (SF-12). 28 The treating IBD specialists were blinded for the patients' CUCQ answers and were asked to fill in a simultaneous assessment of current disease activity using the Harvey-Bradshaw Index (HBI) for CD 29 and the Simple Clinical Colitis Activity Index (SCCAI) for UC. 30 We reviewed the hospital case records and clinical information systems to extract information regarding diagnosis, disease extent, and demographic data.
Psychometric analysis
We used the Statistical Package for Social Sciences version 19, to undertake the required psychometric testing.
Assessing internal consistency
Internal consistency is the form of reliability that assesses the correlation between different items in the scale. We assessed the internal consistency of CUCQ by calculating the Cronbach's α, which should exceed 0.7 for good consistency. 31 We considered individual questions for rejection if their correlations with the total (item-total correlation) score fell below 0.2 31, 32 ; or if more than 80% of patients gave the same response, because such questions are not sensitive enough to discriminate between different levels of severity. 
Identifying the underlying factors
We carried out principal component analysis to assess the underlying dimensions of the CUCQ. 32, 33 Principal component analysis is a statistical technique for determining those questions which fit together as specific factors (or components or domains) and which account for the most variance in the scale. We considered factors important if their corresponding 'Eigen value' (a statistical measure of power to explain variation between patients) exceeded 1.2 and they explained more than 5% of the variance. 22, 32 We considered questions as making a useful contribution to the scale if they had a factor loading of at least 0.4 on one of these important factors. We considered questions not contributing to any important factor in this way for removal from the final instrument.
Stepwise regression of the individual items on the total score
Stepwise regression is a statistical technique for exploring the relationship between a dependent variable 'predicted' (CUCQ total score) and several independent variables 'or predictors' (CUCQ questions). It seeks the best combination and the fewest possible number of CUCQ questions that best predicts the total score. 34, 35 We used this method to minimize the number of items in the CUCQ to produce a short version.
Assessing validity
Construct validity assesses the consistency of the scale with other instruments known to assess similar attributes with good validity and reliability. 32 It is commonly assessed by Pearson's correlation coefficient (r). We used two generic QoL measures (SF-12 and EQ5D) and two disease-specific indices (HBI and SCCAI) to assess the validity of CUCQ. If the CUCQ was a valid measure of the effect of IBD on health, we would expect it to show a good correlation (r > 0.4) with other measures of QoL and disease severity. 
Assessing reproducibility (intraclass correlation)
Reproducibility or test-retest reliability assesses the consistency between successive applications of the CUCQ. 31, 32 We assessed reproducibility by sending a retest questionnaire to a subgroup of patients two weeks after they first completed the CUCQ questionnaire. The retest questionnaire also included a transition question asking participants whether their bowel condition had improved, got worse, or remained the same since completing the first questionnaire. We only included those patients who reported "no" change in their condition in the reproducibility analysis, since the two sets of responses should be consistent. We assessed the reproducibility of scores for these stable patients using the intraclass correlation coefficient. 36 An intraclass correlation between the first and second set of questionnaires should exceed 0.75 for good reproducibility. 
Assessing responsiveness
Responsiveness is the ability of the CUCQ to detect change. In contrast to reproducibility, we assessed responsiveness in retested patients who "did" report a change in their bowel condition (got worse or improved). To do so we used the responsiveness ratio (RR), 36 calculated by dividing the mean change in scores for patients who reported a change by the standard deviation (SD) of the scores of stable patients. We also calculated the standardized response mean (SRM) by dividing the mean change in scores of patients with improvement or deterioration between the baseline and second assessments by the SD of the differences of scores between the two visits. 36 The responsiveness statics should exceed 0.5 for good responsiveness. 31, 32 
Results
Devising and pre-testing items
The expert panel included authors of the UK-IBDQ, a 30-item questionnaire that was validated in 2000 on patients with stable IBD managed in the community. 21 The initial draft of the CUCQ was derived from the UK-IBDQ. The panel recognized that the UK-IBDQ questions should be modified to cover a wider spectrum of patients with IBD, and with an aim to shorten the questionnaire to include the fewest possible questions. We included two questions to assess nocturnal diarrhea and rectal bleeding to cover inpatients with acute IBD. The process of literature review, patient focus group and expert panel opinion identified 32 questions for assessing the QoL in IBD, named the CUCQ-32 (Appendix 1). The response options included a mixture of closed-ended ordinal answers and four-level Likert scales. When asking about loose or runny bowel movements, blood in stools, feeling tired, frequent bowel movements, feeling full of energy, opening bowel accidentally, feeling generally unwell, pain in abdomen, unable to sleep well, getting up to use toilet, passing large amount of wind, feeling off food, having bloated abdomen, going back to toilet immediately after emptying bowel, rushing to toilet, and feeling sick, the response options were changed from the four-level Likert scale (not at all, 1-2 days, 3-7 days, and 8-14 days) that was previously used in the UK-IBDQ to closedended ordinal answers where patients choose from 0-14 days. This change in response options was done to avoid the ceiling effect 23 when assessing patients with acute IBD. The remainders of the questions were answered on a four-level Likert scale. The final version of the questionnaire included 32 questions (Appendix 1).
Scoring
Responses for the Likert scale were scored 0-3, while responses for the closed-ended questions were 0-14. In order to avoid acquiescence bias (yes-set), 37, 38 which describes the general tendency of a patient to provide the highest possible answers regardless of the content of the questions, three questions about happiness, being relaxed, and having energy were phrased in a way so that the higher the number, the higher the level of QoL for that attribute. Their scores were then reversely coded before adding them to the total score. The resulting CUCQ-32 sums all the 32 question scores to yield the total score; the range of scores can be from 0-272; the higher the score, the worse the QoL.
The pretesting pilot study on 20 patients with stable IBD (10 UC and 10 CD) aged from 30-55 years showed that the questions were clear to patients and there was no ambiguity. No additional questions were added or suggested as a result of the pilot study. The mean completion time for CUCQ-32 was 10 min (±3 min).
Patient sample
There were 212 patients who completed and returned the CUCQ-32 questionnaires. Seven patients (3.3%) were excluded from the study analysis because of incomplete responses to the questionnaire and missing data. No specific questions were particularly not answered by patients. A total of 205 patients completed the CUCQ, of whom 104 (50.7%) had CD and 101 (49.2%) had UC. The spectrum of disease severity was very similar between the two forms of IBD (CD vs. UC), with no significant difference in mean scores for EQ5D utility or SF-12 or disease severity as rated by physician global assessment. The characteristics of the patients' sample at baseline are summarized in Table 2 .
Psychometric analysis of the CUCQ
With respect to internal consistency and item-total correlations, the homogeneity of the CUCQ-32 was excellent, with Cronbach's α equal to 0.88. Correlations of each of the 32 items with the total score exceeded 0.2 (Table 1) . No response rate exceeded 80%. Hence, there was not a redundant item. These findings suggest that the individual items within the questionnaire are measuring aspects of the same construct (health-related quality of life (HRQoL) and that there is a consistency within the questionnaire. Using the 15% recommended value for the percentage of patients who score the highest or the lowest scores 23 , there was no ceiling or flooring effects in the CUCQ-32.
The KMO measure of sampling adequacy (=0.816) and Bartlett's test of sphericity (p < 0.001) confirmed that the sample was suitable for principal component analysis. Principal component analysis showed that there were four main factors (Table 3) . Items were attributed to factors if they had a factor loading of at least 0.4. Items with loadings that differed by more than 0.05 on two factors were attributed to the factor with greater loading. 32 To facilitate interpretation, we attributed each question to one of the principal factors according to its factor loading. Attribution of the 32 items to their factors showed that the first factor covers bowel symptoms, the second factor covers psychological impact, the third factor covers social impact, and the fourth factor covers general symptoms.
CUCQ-32 had significant (p < 0.05) and good correlations with EQ5D (r = 0.56), both in the physical (r = 0.63) and mental components (r = 0.58) of SF-12. A subgroup of 68 patients (30 patients with UC and 36 patients with CD) repeated and returned the CUCQ-32 after 2 weeks (the average return time was 15 ± 5 days). We included 38 patients who reported no change in their health in the reproducibility analysis: the intraclass correlation coefficient was 0.95, which is very good. We included the remaining 30 patients who reported changing health in the responsiveness analysis. The number of patients who reported change in their health (n = 30) was not enough to justify separating those who improved from those who deteriorated. The responsiveness statistics for CUCQ-32 were very good. The RR was 0.85 and SRM was 0.99.
We carried out a stepwise regression analysis to identify the smallest possible combination of questions to develop a shorter version of the CUCQ. To avoid having different weights for the different questions when carrying out a stepwise regression, we scaled the 32 answers to a 0-1 score. Scores of the four-level Likert scale answers were divided by 3 and scores of the 0-14 closed-ended ordinal answers were divided by 14 to make sure the questions contributed equally in the stepwise regression model. So, for example, if the score of the fourlevel Likert scale was 2, it was divided by 3 and its score would have been 0.67 and if the score of a closed-ended ordinal answers was 7, it was divided by 14 and its score would have been 0.50.
Regressing the 32 questions on the total CUCQ-32 score identified eight questions that contributed to more than 95% of the variance (Table 4) . These eight items were chosen for the short form of CUCQ, called CUCQ-8 (Appendix 2). Standard psychometric analysis of the data from the 205 patients who filled out the original CUCQ-32 questionnaire indicated that CUCQ-8 items had very good internal consistency, with a Cronbach α value of 0.84. CUCQ-8 had excellent correlation with the original CUCQ-32 (r = 0.91, p < 0.05). It had significant (p < 0.05) and good correlations with EQ5D (r = 0.58), both for the physical (r = 0.65) and mental components (r = 0.63) of SF-12. However, CUCQ-8 had a moderate but positive correlation with the disease severity indices, which were HBI (r = 0.38) and SCCAI (r = 0.35) ( Table 5 ). Most of the CUCQ-8 items correlated well with SF-12 and EQ5D. There was no ceiling or flooring effect in the CUCQ-8.
A subgroup of 68 patients repeated and returned the CUCQ questionnaire after 2 weeks. We included 38 patients who reported no change in their bowel condition in the reproducibility analysis. The intraclass correlation coefficient of CUCQ-8 was 0.94. We included the remaining 30 patients who reported changing bowel condition in the responsiveness analysis. The RR was 0.64 and SRM was 0.89, which are above the required value of 0.5.
Discussion
Assessing the HRQoL in patients with IBD is an important component of medical management and clinical decision-making. The last decade has seen a rapid increase in the number of measures to assess the HRQoL in patients with IBD.
15,17,21,39-48 The commonly used one is the McMaster IBDQ. [14] [15] [16] 20 However, none has been established in routine clinical practice because of the time and effort required to fill out lengthy questionnaires and the cost of the licensing fees of some questionnaires. Most of the disease-specific QoL measures for IBD in current use have been validated on stable outpatients with IBD. There is a pressing need to develop a short and valid HRQoL measure in patients with IBD that is user friendly and supports patient care. The aim of this study was to develop a new HRQoL measure in IBD that is short, reliable and valid for patients with acute as well as stable IBD.
We produced a set of 32 questions (Appendix 1) to assess the QoL on the basis of a thorough literature review and by consulting with a group of experts and patients who reviewed and modified a previously validated QoL measure for use in patients with IBD managed in the community, the UK-IBDQ. 21 The CUCQ-32 differs from the UK-IBDQ questionnaire. We added two questions to cover the symptoms of patients with acute and severe IBD (rectal bleeding and nocturnal diarrhea). We also chose a combination of closedended ordinal answers and four-level Likert scale answers to avoid the ceiling effect and improve the discriminative ability of CUCQ in acute unwell patients. This generated an initial set of 32 questions, named the CUCQ-32, covering acute unwell as well as stable patients. A pilot study confirmed the clarity and relevance of the items. We tested the validity of the CUCQ-32 on 205 patients. From this we derived the CUCQ-8 (Appendix 2), a short QoL measure for IBD patients using a stepwise regression process. Stepwise regression helped the reduction of the CUCQ-32 by selecting the smallest number of items that represented the majority of the scores. The eight validated questions in the CUCQ-8 explained more than 95% of the variance of the CUCQ-32 questions in both UC and CD.
The CUCQ-32 differs from the McMaster IBDQ [14] [15] [16] 20 in several aspects. The wording of the questions in the CUCQ-32 is modified and Anglicized for use in the UK. The response options of the CUCQ-32 were simplified using a combination of closed-ended ordinal answers and four-level Likert scale answers instead of the seven-level Likert answers used in the IBDQ. In order to avoid acquiescence (yesset) bias 37, 38 , three questions about happiness, being relaxed, and having energy were phrased in such a way that the higher the number, the higher the level of QoL for that attribute. Their scores were then reversely coded before adding them to the total score. The items covered by both the CUCQ-32 and the IBDQ-32 are relatively the same. Therefore we did not use the IBDQ in the construct validity testing of the CUCQ-32, but used the SF-12, EQ5D, and disease severity indices instead. However, the CUCQ-32 includes a question about urgency and rushing to toilet, which does not exist in the IBDQ-32. The IBDQ-32 asks about the need to get up at night to go to the toilet and lack of good sleep in one question, while the CUCQ-32 ask about these two items in two separate questions. The advantage of using the CUCQ-32 is its simplicity, the wider coverage of symptoms of acute IBD, and the fact that it is free to use by healthcare professionals.
The potential drawback of shortening any measure is the possibility of compromising its psychometric properties of validity and reliability. However, we analyzed the data from the 205 patients who completed the CUCQ-32 questionnaire, and the results showed that the CUCQ-8 has excellent validity and reliability. It had good internal consistency, with a Cronbach's α value of 0.84, well above the threshold of 0.70 proposed by Nunnally. 22 The CUCQ-8 was consistent with CUCQ-32 and the generic measures of QoL (SF-12 and EQ5D). The CUCQ-8 had a moderate but positive correlation with disease-specific indices. One would expect such correlation, because the QoL questionnaires and disease severity indices measure different disease outcomes. The CUCQ-8 will, however, need further validation studies in a variety of groups of patients, and the correlation with other disease-specific clinical indexes will need to be assessed. Reproducibility was excellent, with an intraclass correlation coefficient of 0.94. The good RR of 0.64 suggests that the CUCQ-8 is responsive to changes in a patient's clinical condition, and is suitable for longitudinal monitoring of QoL. Validation is an ongoing process, and further studies are needed to validate the CUCQ-8 in a variety of groups of patients with IBD.
We limited the validation of the CUCQ-8 to patients without perianal disease. It therefore needs further development and testing before we can use it in this subgroup of patients. Currently we are working to develop and validate two CUCQ supplementary extensions to cover symptoms of patients with perianal disease and patients with stoma.
As we chose patients whose first language was English, further studies are needed to confirm the validity, or modify the CUCQ-8, for patients who are not fluent in English.
We assessed responsiveness to change from participants' subjective perceptions of their bowel condition using transition questions. A retest questionnaire was sent to patients within 2 weeks. In addition to the CUCQ-8, the retest questionnaire asked patients for a general rating of changes in their bowel condition since completing the first questionnaire. Transition questions in test-retest validation analysis has been used in several outcome measures studies and is considered advantageous over other methods for assessing the QoL because it directly addresses patients' perceptions of change over time and is short and simple. 21, 39, [49] [50] [51] Those who reported "no" changes were included in the reproducibility analysis, while those who reported a change in their bowel condition were included in the responsiveness analysis. Subjective measures give insights into matters of human concern, such as pain, suffering or depression that cannot be deduced solely from physical measurements or laboratory test results. 52 Further studies are needed to assess the reproducibility and responsiveness of CUCQ-8 using other health indicators, such as clinical judgment or endoscopy. Table 4 . Stepwise regression of the CUCQ-32 questions.
Items of CUCQ-32
Cumulative % of variance 1.On how many days over the last two weeks have you felt generally unwell? 64.7% 2.On how many days over the last two weeks have you felt pain in your abdomen? 80.5% 3.In the last two weeks did your bowel condition prevent you from going out socially?
86.1% 4.On how many nights in the last two weeks have you had to get up to use the toilet because of your bowel condition after you have gone to bed? 90.2% 5.On how many days over the last two weeks has your abdomen felt bloated?
92.4% 6.On how many days over the last two weeks have you felt tired?
93.8% 7.In the last two weeks have you felt upset?
95.0% 8.On how many days over the last two weeks have you had to rush to the toilet?
95.9% 9.On how many days over the last two weeks have you felt full of energy?
96.7% 10.On how many days in the last two weeks have you noticed blood in your stools?
97.1% 11.On how many days over the last two weeks, have you had a problem with large amounts of wind?
97.5% 12.On how many days over the last two weeks have you opened your bowels more than three times a day?
97.9% 13.In the last two weeks, has your bowel condition prevented you from carrying out your work or other normal activities? 98.2% 14.In the last two weeks have you been embarrassed by your bowel problem?
98 There is no rule in the literature about the number of patients required to validate the QoL measures. However, a ratio of 5 or 10 patients per item has been suggested. 22 Recent studies suggest that a minimum of 100 patients is sufficient for a proper validation study. 23 We analyzed data from 205 patients, and the KMO measure of sampling adequacy (KMO = 0.816) and Bartlett's test of sphericity (p < 0.001) confirmed that the sample was suitable for principal component analysis. The sample size we had was not sufficient enough for a reliable subanalysis of the different phenotypes of IBD (i.e. CD versus UC). However, we are undertaking an ongoing validation process to validate the CUCQ-32 in a larger group of patients with different presentations of IBD.
There is unavoidable selection bias when asking patients to fill in questionnaires, as not all of them will be willing to participate. However, the sample was drawn from four of the main hospitals in south Wales to ensure a good representation of patients and to mirror routine clinical practice. The CUCQ-8 needs to be validated in a larger group of patients with more diverse demographic and clinical characteristics. In the meantime, the CUCQ-8 performed well in its present form and showed very good psychometric properties in the current study.
Our findings support the validity, internal reliability, reproducibility and responsiveness of the CUCQ-8, a short QoL tool for patients with IBD. Furthermore, this new tool has been shown to be acceptable to patients in the UK, and is shorter and more easily applied in clinical practice than existing QoL measures. It will be available free for healthcare providers to support patient care without licensing fees. We therefore anticipate that it will be widely used, both in normal clinical practice and in health care evaluation to assess the effect of interventions on QoL. The simplicity, validity and reliability of the CUCQ-8 make it a strong candidate for IBD registries and databases, and in audits that assess the efficacy of new treatments in IBD, for example biological therapy.
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The following questions ask for your views about your bowel problem and how it has affected your life over the last two weeks. Please answer all the questions. If you are unsure about how to answer any question, just give the best answer you can. Do not spend too much time answering, as your first thoughts are likely to be the most accurate. If you do not wish to answer any of these questions, please leave it blank and complete the details of the question and reason(s) why it was not answered. 
